Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of tovinontrine in chronic heart failure with reduced ejection fraction
NL-OMON60471Phase 2Completed
- Sponsor
- Cardurion Pharmaceuticals
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tovinontrine in heart failure with reduced ejection fraction (HFrEF), sponsored by Cardurion Pharmaceuticals. Primary endpoint: Percent change from baseline in plasma NT-proBNP for Doses 2 and 3 at Week 12. Started Sep 2024; status: completed.
02
Drugs
tovinontrine
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NL-OMON60471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60471.